The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi Sprout45,
I do not believe it is by luck our SP has kept above 16p of late i.e. when it has dropped below 16p it has returned back above in the same day Trading ?!!!
RF will pay our Genedrive £168,000 on exercise of their 682,730 warrants, that they received from the £300,000 drawdown.
It seems to me RF are selling just the right amount of their shares to keep the SP as low as they can around the 17p level, but hold off from selling at a level that would keep the SP below 16p - they want to receive future warrants from future drawdowns - which means they need the SP to stay above 16p, in order that our Genedrive can drawdown further £300,000 monthly amounts?.
I believe RF want the warrants, because they foresee our SP rising nicely, and RF will do very well from these warrants?!!
Well this is how I see it anyway!!!
The above is all -- IMHO
From the RNS:-
''Investors have been granted 682,730 warrants equal to 40% of this drawdown divided by the Reference Price of 17.57648 pence. The exercise price of the warrants payable to the Company will be 140% of the Reference Price equating to 24.6071 pence.''
So how does this work out:-
40% of this drawdown = 40% of £300,000 = 120,000, and 120,000 divided by the reference price of 17.57648 pence = 682,730 warrants
The exercise price of these 682,730 warrants is 140% of the reference price of 17.57648p = 140% x 17.57648 = 24.6071p payable to the company.
Therefore 682,730 warrants x 24.6071p = £168,000
Yea could be Tuesday, but my thinking is Monday?
Much to look forward to:-
. Devote funding - £Value
. ''and other aligned funding.''? !!
. As well as: In-kind contributions - Details
. FDA Update
. Full validation of the stroke test
. Continued rollout of AHIL in the UK, then Europe, and the rest of the World.
. Notification of increased AIHL Test Sales.
. Continued working with the NHS, and how this will be scheduled.
. Notification of further new Products.
. Good Financial Position.
. Our SP rising.
All the above is IMHO !!
Hi MyIPA,
Last year our Final Results for the year ending 30th June 2022 were delivered on the 21st November 2022.
Our half year ended 31st December 2022 and were delivered on 31st March 2023.
As far as I am aware we only receive Half year and Full year Final results, and therefore I do not expect to see our next results for the year ending today June 30th until November this year 2023 ?
yep of co**** you are a gdr shareholder - lol -
a reminder of your posts on the 20th june 2023 -
stockpickfree
posted in: gdr
posts: 337
price: 16.00
no opinion
re: time to buy!20 jun 2023 16:20
''the exact inverse is true. it’s still not too late to sell. although you’d have been better off doing so in the 20’s when i first started arguing this. this is going down to single figures under the pressure of rf’s constant selling.
you longs need to have a look at the sunk cost fallacy. because your “reasoning” here is illogical and fallacious.''
''the exact inverse is true. it’s still not too late to sell. although you’d have been better off doing so in the 20’s when i first started arguing this. this is going down to single figures under the pressure of rf’s constant selling.
you longs need to have a look at the sunk cost fallacy. because your “reasoning” here is illogical and fallacious.''
stockpickfree
posted in: gdr
posts: 337
price: 16.00
no opinion
re: missing persons alert20 jun 2023 11:02
''smart move..
you don’t catch a falling knife, you drop it and bind up the wound it caused you.
gdr will have it’s time in the sun at some future date. but stubbornly holding on as rf continues to dump is madness. buy back in when they have finished selling.''
You are right starres - in my Native Language - when you mention an investment opportunity to your wife, and she Buys in - and you do not tell her not too - then this is considered to be a Recommendation LOL
For starres eyes only !!! LOL
RNS Number : 6932U
Genedrive PLC
30 March 2023
Genedrive® MT-RNR1 ID Test receives positive final recommendation by NICE
NICE issues final guidance for use in the NHS through Early Value Assessment programme
genedrive plc (AIM:GDR), the point of care molecular diagnostics company, announces that, further to the Company's announcement on 9 February 2023, the UK's National Institute for Health and Care Excellence (NICE) has today ratified and finalised its recommendation following a public consultation process that the Genedrive® MT-RNR1 ID Kit ''can be used by the NHS.''
NICE recommends CYP2C19 genotyping for clopidogrel treatment
RNS Number : 9399Z
Genedrive PLC
19 May 2023
Genedrive® CYP2C19 ID test modelled to be a clinically and cost-effective option
genedrive plc (AIM: GDR), the point of care molecular diagnostics company, announces that the UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance that CYP2C19 genotyping should be used before clopidogrel administration in the management of ischemic stroke ("IS") patients.
Looking Good !!
LOL - so starres recommended GDR to his wife at an average SP of £1.90, and now she is his Ex-Wife - No wonder he is still hanging around here as a Non-Shareholder - that is an Almighty Grudge he is carrying - starres needs to realise it is his fault she left him, not GDR's LOL
The only Post that the Non-Shareholding starres seems to have got right, when he posted:-
''Lack of volume here going to become increasingly problematic for SP me thinks....''
Well our SP certainly has shown to be problematic today - to himself - LOL - UP 10.94% TODAY !!
Market Summary >
Genedrive PLC
17.75 GBX
+1.75 (10.94%)today
29 Jun, 16:30 BST
I do not believe that Idiot Nathan can read - (He is also posting his Rubbish on Multiple Bulletin Boards)
Where it states +1.50 (9.38%) - This means our SP is going UP - LOL
Market Summary >
Genedrive PLC
17.50 GBX
+1.50 (9.38%)today
29 Jun, 13:00 BST
LOL stockprickfree,
See's our SP is rising, and now says he is invested LOL
This is the post he posted on the 20th June - and he has only posted negatively towards our GDR since this post:-
stockpickfree
Posted in: GDR
Posts: 333
Price: 16.00
No Opinion
RE: Time to buy!20 Jun 2023 16:20
''The exact inverse is true. It’s still not too late to sell. Although you’d have been better off doing so in the 20’s when I first started arguing this. This is going down to single figures under the pressure of RF’s constant selling.
You longs need to have a look at the sunk cost fallacy. Because your “reasoning” here is illogical and fallacious.''
Good Morning MyIPA,
Just the thought of them, gives me an Irritating Itch ''CRINGY''.
Our first £300,000 drawdown was announced on the 2nd June 2023.
So hopefully we will hear soon of the 2nd £300,000 drawdown, with a further circa £160,000 payment due to be paid to our Genedrive, on exercise of RF's second grant of warrants !!
''DEVOTE pulls together health economists, clinicians, informaticians, and researchers to quickly access new technologies, and provide feedback in an iterative fashion. Genedrive's CYP2C19 ID Kit is one of three exemplar projects to be included in the programme which is expected to be funded through the 'Innovate grant', 'in-kind contributions', 'and other aligned funding.''
. So Innovate Grant incoming !!
. ''and other aligned funding.'' !!
. As well as: In-kind contributions - which can include:-
. Voluntary labour (time or services ‘donated’ should be additional and not part of the persons' normal job).
. Donated equipment.
. Services donated from other companies or organisations.
. Use of premises or office space for the project.
The term “In-kind contribution” is described as non-financial assets that are being put at the disposal of a partnership and which can be used both in the context of external calls (e.g. a research infrastructure) or of in-kind activities (e.g. a dataset for use in a common R&I programme).
It was Good to see RF fund us with the first drawdown of £300,000, plus a further payment of £168,000 pounds for their grant of 682,730 warrants, at the Reference Price equating to 24.6071 pence!!
So a Total payment to our Genedrive of £468,000 pounds, and possibly somewhere near this same amount coming again soon ?!!
Looking forward to the DEVOTE funding announcement!!
We know that we spend circa £125,000 per product development per month, and we usually have two products in development at any one time.
So it will be interesting to see whether DEVOTE Funding will now cover this same level of development costing/products going forward?!!
If they do then I take it that means we will not need to fork out the £250,000 of Development costs each month - which in turn could reduce our Monthly running costs from £400,000 per month to £150,000 per month - now that would have a Great Positive impact on our financial situation?!!
We also know that 'Sales of our AIHL Test are going on in the Background' - Looking forward to hearing how well the Quantity is Growing?!!
Well this is how I see our position anyway !!
The above is all -- IMHO